MedTrace Logo

Delivra-Celecoxib 8% Cream and Osteoarthritis

NCT03882749 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2019-03-20

No results posted yet for this study

Summary

The observation of the clinical use of the Delivra Celecoxib cream (8%) in the treatment of osteoarthritis of the knee. Observations will be made over 12 weeks of treatment. Evaluations include: pain, functionality and patients global assessment of disease. Patients will self administer treatment as prescribed.

Conditions

  • Osteoarthritis, Knee

Sponsors & Collaborators

  • Delivra, Inc.

    lead INDUSTRY

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-07-23
Completion
2019-10-23

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03882749 on ClinicalTrials.gov